Skip to main content
. Author manuscript; available in PMC: 2017 Aug 19.
Published in final edited form as: ACS Chem Biol. 2016 Jun 6;11(8):2105–2111. doi: 10.1021/acschembio.6b00217

Figure 3.

Figure 3

YKL-05-099 modulates inflammatory cytokine responses in vivo. A) and B) IP administration of the indicated doses of YKL-05-099 for 15 min prior to stimulation with LPS (0.5 mg/Kg) for 1 hr reduces p-HDAC5 (Ser259) levels in total splenic leukocytes and modulates serum IL-10 and TNFα levels (bars = mean; n = 3 mice; data is representative of 2 independent experiments). ***, P < 0.001; *, P < 0.05 using two-way ANOVA with Dunnett post-test. C) and D) IP administration of YKL-05-099 (20 mg/Kg) for 15 min prior to stimulation with LPS (0.5 mg/Kg) modulates serum IL-10 and TNFα abundance and colonic mRNA levels without affecting IL-6 responses (mean ± SD; n = 3 mice per time point; data is from 1 independent experiment). ***, P < 0.001; **, P < 0.05; *, P < 0.05 using unpaired Student’s t tests.

HHS Vulnerability Disclosure